Ashland account plan
Global additives specialty ingredients company
At a glance
Ashland (NYSE: ASH) is a global additives and specialty ingredients company: $1.863 billion fiscal 2026 sales, about 2,800 employees.
Ashland Inc. (NYSE: ASH) makes additives and specialty ingredients for pharmaceutical, personal care, food and beverage, architectural coatings, construction and energy customers in more than 100 countries, built mainly on cellulosics and polyvinylpyrrolidone (PVP) chemistries. It is headquartered in Wilmington, Delaware, with principal offices in Bridgewater, New Jersey, and its fiscal year ends September 30. Fiscal 2026 sales were $1.863 billion, up 2%, with Adjusted EBITDA of $385 million and net income of $4 million, after a $845 million net loss in fiscal 2025. The company had approximately 2,800 employees at the November 2026 results release, and 73% of fiscal 2025 sales were outside North America.
Business units
Life Sciences
35% of fiscal 2025 sales; $671 million fiscal 2026 salesExcipients and tablet coating systems for oral solid dosage drugs, plus injectables, nutrition, agricultural chemicals, diagnostic films and fine chemicals, sold to pharmaceutical and food and beverage manufacturers. In Q4 fiscal 2026 sales rose 4% to $180 million, pharma grew about 6% and the Adjusted EBITDA margin reached 35.6%, the highest in the segment's history. It is led by Alessandra Faccin, who also runs Intermediates.
Personal Care
32% of fiscal 2025 sales; $592 million fiscal 2026 salesBiofunctional actives, microbial protectants, skin, sun, oral and hair care ingredients and household solutions, many natural or nature-derived, sold from multinational consumer brands to small boutique companies. Q4 fiscal 2026 sales rose 8% to $163 million with a 30.1% Adjusted EBITDA margin; the Avoca business was sold to Mane SA in March 2025. Jim Minicucci leads the segment.
Specialty Additives
28% of fiscal 2025 sales; $504 million fiscal 2026 salesRheology and performance additives such as HEC for waterborne architectural paint, cellulose ethers for dry-mortar construction and products for oilfield fluids, serving over 30 industries. In Q4 fiscal 2026 Coatings grew 9% and Performance Specialties 14%, but Adjusted EBITDA fell 31% to $20 million on lower Hopewell productivity. Dago Caceres leads the segment.
Intermediates
5% of fiscal 2025 sales; $135 million fiscal 2026 salesProduces 1,4 butanediol (BDO) and derivatives including NMP at its main plant in Lima, Ohio, for engineering polymers, polyurethanes and solvents, and supplies BDO to the other segments. It won a multi-year, significant-volume US contract in batteries, EV and energy storage, with new customer wins ramping in fiscal 2027.
Strategic priorities
- Execute, globalize, innovate, invest
- CEO Guillermo Novo says the transformation is done and attention is now on profitable growth. Fiscal 2027 targets are about $10 million of net productivity and manufacturing optimization benefits, about $20 million of incremental Globalize sales and $45 million of innovation-driven sales.
- Fix Hopewell HEC productivity
- Hopewell under-absorption cost about $17.5 million versus plan in fiscal 2026, with about $5 million carrying into Q1 fiscal 2027; output is planned to rise about 25%, with a similar step the following year.
- Regionalize four high-quality businesses
- Globalize focuses on tablet coatings and injectables in pharma and on microbial protection and biofunctional actives in Personal Care, with local commercial, technical and supply resources; it added about $26 million of sales in fiscal 2026 against a $20 million target.
- Commercialize new technology platforms
- Platforms such as transformed vegetable oils, multifunctional starch, super-wetters and sugarcane bagasse cellulose address an independently validated $9 billion market, with an ambition of $200-$300 million of incremental sales in five years; 52 patents have been filed.
- Financial algorithm
- Growth 200-300 basis points above market, Adjusted EBITDA margin above 25% and free cash flow conversion above 50%, as set out by CFO William Whitaker at the September 2026 Innovation Day.
Latest results
In Q4 fiscal 2026 (quarter to September 30, 2026) sales rose 4% to $498 million, with volumes up 3% and pricing up 2%, while Adjusted EBITDA rose to $121 million at a 24.3% margin. For fiscal 2026, sales were $1.863 billion (organic +3% excluding Avoca) and Adjusted EBITDA $385 million versus $401 million, a 20.7% margin. Operating cash flow rose to $385 million and Ongoing Free Cash Flow to $232 million; year-end net debt was $891 million and net leverage 2.3x. Fiscal 2027 guidance is sales of $1,905-$1,975 million, Adjusted EBITDA of $405-$435 million and Ongoing Free Cash Flow conversion above 40%.
Investments and deals
- Capex step-up and HEC debottlenecking
- Fiscal 2027 capex is guided at up to about $140 million, versus $88 million in fiscal 2026, as HEC debottlenecking is pulled forward from 2029-2030 to be ready for a possible coatings and housing recovery.
- Injectables capacity
- Seven high-purity injectables launches since 2022, over $100 million of active sales opportunities and expansions in Ireland and Columbus.
- Portfolio divestments
- Nutraceuticals was sold in August 2024 and Avoca to Mane SA in March 2025 (proceeds $16 million); portfolio actions cut sales by approximately $208 million in fiscal 2025.
- Manufacturing optimization plan
- A multi-year plan targets $50 million to $55 million of pre-tax savings, and $60 million as market conditions improve, particularly in China.
- Bolt-on M&A
- Capital discipline leaves room for bolt-on M&A, with pharma a big area of focus, and for buying regional assets; maintenance capex runs about $50-$65 million a year.
Challenges and risks
- Operational reliability
- The Calvert City equipment failure cost about $15 million and weather about $5 million in fiscal 2026; the CEO said the miss was on the operating side, not in markets.
- Weak energy and construction demand
- Specialty Additives took a roughly $30 million net hit in energy and resources, and construction volumes were cut deliberately to prioritize higher-value applications.
- Raw materials, tariffs and currency
- Ashland is exposed to volatile raw material and energy costs (cotton linters, wood pulp, guar), tariffs on imports from China, the EU and India, and expects currency headwinds of $20-$25 million on fiscal 2027 sales.
- Debt and legacy liabilities
- Total debt was $1,384 million at fiscal 2025 year-end, and asbestos and environmental liabilities remain, with environmental reserves of $226 million.
What leadership says
“Our priorities are clear: improve operating performance, drive productivity across our network, maintain pricing discipline, build on our commercial momentum and continue to scale our globalize and innovate initiatives.”
“The miss was in the operating side.”
“A few years ago, we were talking about potential. Now we're talking about commercialization.”
“The question is not whether one project wins, it is whether the portfolio performs.”
Where a supplier can help
- Plant productivity and reliability
- The Hopewell productivity priority and the Calvert City outage point to demand for maintenance, process control and manufacturing performance tools across the plant network.
- Capacity projects
- The capex step-up to up to about $140 million for HEC debottlenecking and injectables expansions opens room for engineering, equipment and construction suppliers.
- Regional go-to-market support
- The Globalize priority builds local commercial, technical and supply resources for four businesses, a fit for regional distribution, logistics and sales-enablement partners.
- Scaling new platforms
- Commercializing new platforms relies on idle capacity and tolling partners, so contract manufacturers and regulatory or application-testing services can help speed scale-up.
- Raw material and trade risk
- Volatile raw materials, tariffs and currency headwinds make sourcing, procurement analytics and trade-compliance services relevant.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Ashland?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Ashland Inc. Annual Report on Form 10-K for fiscal year ended September 30, 2025
- Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with approximately 2,900 employees serving customers in more than 100 countries; fiscal year ends September 30.
- Four reportable segments in fiscal 2025: Life Sciences (35% of sales), Personal Care (32%), Specialty Additives (28%) and Intermediates (5%).
- Fiscal 2025 sales were $1,824 million, down $289 million or 14% from $2,113 million, driven by divestitures (-$153 million), lower volume (-$98 million) and price/mix (-$46 million); portfolio optimization actions cut sales by approximately $208 million.
- Net loss of $845 million (-$18.23 per diluted share) after a $706 million non-cash goodwill impairment ($375 million Life Sciences, $331 million Specialty Additives) and a $175 million net Avoca impairment and sale; Adjusted EBITDA fell to $401 million from $459 million.
- Sales are 73% outside North America: Europe 37%, North America 27%, Asia Pacific 26%, Latin America & other 10%.
- Restructuring: a $30 million plan (approximately $20 million realized in fiscal 2025) and a multi-year manufacturing optimization plan targeting $50 million to $55 million of pre-tax savings ($60 million as markets, particularly China, improve).
- Avoca business sold to Mane SA (proceeds $16 million); Nutraceuticals sold in August 2024.
- Capex was $98 million in fiscal 2025 and is expected to average approximately $100 million per year over the next three years; total debt $1,384 million, available liquidity $811 million, no bond or revolver maturities until fiscal 2027.
- Main risks: tariffs and trade policy, raw material and energy volatility (cotton linters, wood pulp, guar), substantial indebtedness, asbestos and environmental liabilities (environmental reserves $226 million).
- Ashland reports fourth quarter and full-year fiscal 2026 results and issues outlook for fiscal 2027 (Form 8-K Exhibit 99.1)
- Q4 fiscal 2026 (quarter to September 30, 2026): sales $498 million, up 4% (volume +3%, pricing +2%, currency about -1%); Adjusted EBITDA $121 million, up 2%, margin 24.3%.
- Loss from continuing operations $17 million (-$0.36 per diluted share); adjusted EPS excluding intangibles amortization $1.12 (vs $1.08).
- Fiscal 2026: sales $1.863 billion, up 2% (organic +3% excluding Avoca); Adjusted EBITDA $385 million (vs $401 million), margin 20.7%; net income $4 million versus a $845 million loss.
- Life Sciences Q4 sales $180 million (+4%), pharma about +6% and a sixth consecutive quarter of volume growth; Adjusted EBITDA margin 35.6%, the segment's highest ever.
- Personal Care Q4 sales $163 million (+8%), Adjusted EBITDA margin 30.1%; Specialty Additives Adjusted EBITDA down 31% to $20 million on lower Hopewell productivity.
- Cash: FY operating cash flow $385 million, Ongoing Free Cash Flow $232 million; year-end cash about $480 million, net debt $891 million, net leverage 2.3x.
- Globalize and Innovate each generated about $26 million of incremental sales in fiscal 2026, beating targets of $20 million and $15 million.
- Fiscal 2027 guidance: sales $1,905-$1,975 million, Adjusted EBITDA $405-$435 million, Ongoing Free Cash Flow conversion above 40%, capex up to about $140 million.
- Ashland Q4 and full-year fiscal 2026 earnings call transcript
- Guillermo Novo (Chair and CEO) framed fiscal 2026 as strong commercially but held back by operations: "The miss was in the operating side."
- Life Sciences delivered a record Adjusted EBITDA margin of about 36% and Personal Care above 30%; Personal Care's leader is now targeting "that mid-30% range".
- Hopewell (HEC) under-absorption cost about $17.5 million versus plan in fiscal 2026, of which about $5 million carries into Q1 fiscal 2027; output is planned to rise about 25%.
- Fiscal 2027 guidance: sales $1.905-$1.975 billion, Adjusted EBITDA $405-$435 million, free cash flow conversion above 40% with capex of up to $140 million.
- Capex step-up: HEC debottlenecking pulled forward from 2029-2030 to be ready for a possible coatings and housing recovery.
- Globalize and Innovate generated about $52 million of incremental sales versus a $35 million target; fiscal 2027 targets are about $20 million and $45 million.
- Pricing: down 2 points in Q2, up 2 points in Q4; Novo: "We value price, so this is more about protection."
- On reports of a potential sale, Novo declined comment: "The biggest value creation driver in any scenario you want to do is performance."
- Intermediates won a multi-year, significant-volume US contract in batteries, EV and energy storage.
- Ashland Innovation Day 2026 transcript
- Third Innovation Day (September 17, 2026): CEO Guillermo Novo says innovation has moved from validation to "the exciting commercialization phase".
- Strategy is "Execute, globalize, innovate, invest"; Novo: "we are done with our transformation part" and now focuses fully on profitable growth.
- Globalize focuses on four businesses: tablet coatings and injectables in pharma, microbial protection and biofunctional actives in Personal Care.
- Financial algorithm (CFO William Whitaker): growth 200-300 basis points above market, Adjusted EBITDA margin above 25%, free cash flow conversion above 50%.
- An independently validated $9 billion market opportunity for the new platforms: Specialty Additives $4 billion, Personal Care $3 billion, Life Sciences $2 billion.
- Five-year ambition of $200-$300 million of incremental sales ($400-$600 million at ten years); 52 patents filed.
- Launches: Softhance TVO (silicone replacement in hair care, +$850 million addressable market, launch fiscal 2027), Stabileze S starch (+$300 million, first purchase orders), Permexa sodium caprate for oral biologics and GLP-1s.
- Specialty Additives: TVO TiO2 spacer cuts TiO2 20% for about 12% lower cost and about 15% lower carbon footprint, with over 10 global partners; also sugarcane bagasse cellulose said to be up to 50% cheaper.
- Capital discipline: maintenance capex $50-$65 million a year; "investment follows traction"; bolt-on M&A and buying regional assets considered.
Questions about Ashland
What does Ashland do?
Ashland is a global additives and specialty ingredients company. It sells cellulosics, PVP and other ingredients to pharmaceutical, personal care, food, coatings, construction and energy customers through four segments: Life Sciences, Personal Care, Specialty Additives and Intermediates.
What is Ashland's revenue?
Fiscal 2026 sales (year to September 30, 2026) were $1.863 billion, up 2%, with Adjusted EBITDA of $385 million. Fiscal 2027 guidance is $1,905-$1,975 million of sales.
How many employees does Ashland have?
Ashland had approximately 2,800 employees at the time of its November 2026 results release, down from approximately 2,900 at September 30, 2025.
What is Ashland's strategy?
Its strategy is Execute, globalize, innovate, invest: improve plant productivity, regionalize four high-quality businesses, commercialize new technology platforms and invest with capital discipline, including bolt-on M&A.
Who leads Ashland?
Guillermo Novo is Chair and Chief Executive Officer and William Whitaker is Chief Financial Officer.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)